Ainos (AIMD)
Market Price (5/15/2026): $1.73 | Market Cap: $10.4 MilSector: Health Care | Industry: Pharmaceuticals
Ainos (AIMD)
Market Price (5/15/2026): $1.73Market Cap: $10.4 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Weak multi-year price returns2Y Excs Rtn is -112%, 3Y Excs Rtn is -173% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -72393% Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 106% Expensive valuation multiplesP/SPrice/Sales ratio is 573x Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -83%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -56%, Rev Chg QQuarterly Revenue Change % is -100% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 9237% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -24149%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -24252% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 731% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -139% High stock price volatilityVol 12M is 101% Key risksAIMD key risks include [1] its precarious financial health, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -112%, 3Y Excs Rtn is -173% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -72393% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 106% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 573x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -83%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -56%, Rev Chg QQuarterly Revenue Change % is -100% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 9237% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -24149%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -24252% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 731% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -139% |
| High stock price volatilityVol 12M is 101% |
| Key risksAIMD key risks include [1] its precarious financial health, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Continued Weak Financial Performance and Shareholder Dilution.
Ainos reported a significant net loss of -$14.8 million for the full year 2025 on March 30, 2026, with revenue of only $124.2k. The company has maintained negative EBITDA and pretax profit margins, coupled with high operational expenses, contributing to deep net losses. Furthermore, Ainos has a limited cash runway of less than one year and shareholders experienced substantial dilution, with total shares outstanding increasing by 135.4% over the past year.
2. Negative Analyst Sentiment and Technical Sell Signals.
The single Wall Street analyst covering Ainos issued a "Sell" rating, reflecting a lack of confidence in the company's future prospects. This bearish outlook was reinforced by technical analysis, which generated a "sell signal" on April 17, 2026, from a pivot top point, leading to a subsequent fall of 13.71%.
Show more
Stock Movement Drivers
Fundamental Drivers
The -14.0% change in AIMD stock from 1/31/2026 to 5/14/2026 was primarily driven by a -84.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5142026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.00 | 1.72 | -14.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -84.0% |
| P/S Multiple | 80.6 | 572.8 | 610.9% |
| Shares Outstanding (Mil) | 5 | 6 | -24.5% |
| Cumulative Contribution | -14.0% |
Market Drivers
1/31/2026 to 5/14/2026| Return | Correlation | |
|---|---|---|
| AIMD | -14.0% | |
| Market (SPY) | 8.4% | 44.7% |
| Sector (XLV) | -4.9% | 27.4% |
Fundamental Drivers
The -47.9% change in AIMD stock from 10/31/2025 to 5/14/2026 was primarily driven by a -83.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 5142026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.30 | 1.72 | -47.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -83.7% |
| P/S Multiple | 122.7 | 572.8 | 366.9% |
| Shares Outstanding (Mil) | 4 | 6 | -31.7% |
| Cumulative Contribution | -47.9% |
Market Drivers
10/31/2025 to 5/14/2026| Return | Correlation | |
|---|---|---|
| AIMD | -47.9% | |
| Market (SPY) | 10.3% | 35.7% |
| Sector (XLV) | 2.5% | 20.5% |
Fundamental Drivers
The -35.1% change in AIMD stock from 4/30/2025 to 5/14/2026 was primarily driven by a -48.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302025 | 5142026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.65 | 1.72 | -35.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -12.6% |
| P/S Multiple | 394.5 | 572.8 | 45.2% |
| Shares Outstanding (Mil) | 3 | 6 | -48.8% |
| Cumulative Contribution | -35.1% |
Market Drivers
4/30/2025 to 5/14/2026| Return | Correlation | |
|---|---|---|
| AIMD | -35.1% | |
| Market (SPY) | 36.5% | 31.9% |
| Sector (XLV) | 6.2% | 6.3% |
Fundamental Drivers
The -91.2% change in AIMD stock from 4/30/2023 to 5/14/2026 was primarily driven by a -99.5% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302023 | 5142026 | Change |
|---|---|---|---|
| Stock Price ($) | 19.50 | 1.72 | -91.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 0 | -99.5% |
| P/S Multiple | 4.4 | 572.8 | 12865.8% |
| Shares Outstanding (Mil) | 1 | 6 | -86.8% |
| Cumulative Contribution | -91.2% |
Market Drivers
4/30/2023 to 5/14/2026| Return | Correlation | |
|---|---|---|
| AIMD | -91.2% | |
| Market (SPY) | 86.9% | 10.0% |
| Sector (XLV) | 15.4% | 0.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AIMD Return | 0% | 121% | -34% | -78% | -28% | 4% | -76% |
| Peers Return | 19% | -6% | 10% | -8% | 24% | -8% | 29% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 98% |
Monthly Win Rates [3] | |||||||
| AIMD Win Rate | 0% | 17% | 33% | 25% | 33% | 40% | |
| Peers Win Rate | 55% | 53% | 50% | 50% | 55% | 32% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| AIMD Max Drawdown | 0% | -84% | -75% | -85% | -61% | -45% | |
| Peers Max Drawdown | -17% | -27% | -24% | -24% | -24% | -21% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: AMGN, BMY, JNJ, ZTS, IDXX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/14/2026 (YTD)
How Low Can It Go
| Event | AIMD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -30.3% | -18.8% |
| % Gain to Breakeven | 43.5% | 23.1% |
| Time to Breakeven | 77 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -40.0% | -7.8% |
| % Gain to Breakeven | 66.6% | 8.5% |
| Time to Breakeven | 434 days | 18 days |
| 2020 COVID-19 Crash | ||
| % Loss | -22.4% | -33.7% |
| % Gain to Breakeven | 28.9% | 50.9% |
| Time to Breakeven | 4 days | 140 days |
| 2013 Taper Tantrum | ||
| % Loss | -53.8% | -0.2% |
| % Gain to Breakeven | 116.7% | 0.2% |
| Time to Breakeven | 1596 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -23.3% | -17.9% |
| % Gain to Breakeven | 30.4% | 21.8% |
| Time to Breakeven | 10 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -49.1% | -15.4% |
| % Gain to Breakeven | 96.4% | 18.2% |
| Time to Breakeven | 198 days | 125 days |
In The Past
Ainos's stock fell -30.3% during the 2025 US Tariff Shock. Such a loss loss requires a 43.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | AIMD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -30.3% | -18.8% |
| % Gain to Breakeven | 43.5% | 23.1% |
| Time to Breakeven | 77 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -40.0% | -7.8% |
| % Gain to Breakeven | 66.6% | 8.5% |
| Time to Breakeven | 434 days | 18 days |
| 2020 COVID-19 Crash | ||
| % Loss | -22.4% | -33.7% |
| % Gain to Breakeven | 28.9% | 50.9% |
| Time to Breakeven | 4 days | 140 days |
| 2013 Taper Tantrum | ||
| % Loss | -53.8% | -0.2% |
| % Gain to Breakeven | 116.7% | 0.2% |
| Time to Breakeven | 1596 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -23.3% | -17.9% |
| % Gain to Breakeven | 30.4% | 21.8% |
| Time to Breakeven | 10 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -49.1% | -15.4% |
| % Gain to Breakeven | 96.4% | 18.2% |
| Time to Breakeven | 198 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -86.3% | -53.4% |
| % Gain to Breakeven | 630.8% | 114.4% |
| Time to Breakeven | 3535 days | 1085 days |
In The Past
Ainos's stock fell -30.3% during the 2025 US Tariff Shock. Such a loss loss requires a 43.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Ainos (AIMD)
AI Analysis | Feedback
Like QuidelOrtho for rapid, point-of-care diagnostic tests, enhanced with a cloud-based digital management platform.
An early-stage biotech company akin to Moderna, focused on developing novel RNA technology platforms for therapeutics.
AI Analysis | Feedback
- COVID-19 Antigen Rapid Test Kit: A rapid diagnostic test for COVID-19.
- Ainos' Cloud-based Test Management App: A platform integrating an antigen rapid test kit with personal and enterprise applications for test management.
- COVID-19 Nucleic Acid Test: A diagnostic test that detects the genetic material of the COVID-19 virus.
- Volatile Organic Compounds Point-of-Care Testing: On-site testing for volatile organic compounds.
- Very Low-Dose Oral Interferon Alpha: A low-dose oral formulation of Interferon Alpha for various treatment applications.
- Synthetic RNA (SRNA) Technology Platform: A technology platform under development focusing on synthetic RNA.
AI Analysis | Feedback
Ainos (AIMD) primarily sells its products and technologies to other companies and organizations, rather than directly to individuals. The provided background information does not list the names of specific customer companies. Based on the description of its products and services, Ainos' major customer categories would include:
- Healthcare Providers and Facilities: This category encompasses hospitals, clinics, and diagnostic laboratories that would purchase and utilize Ainos' point-of-care testing solutions (such as COVID-19 antigen and nucleic acid tests, and volatile organic compounds testing). These entities would also be the primary users or prescribers of any approved medical treatments, like Very Low-Dose Oral Interferon Alpha.
- Medical Product Distributors and Pharmacies: These businesses are integral to the healthcare supply chain. They would purchase Ainos' test kits and medical treatments for widespread distribution to other healthcare entities or directly to consumers through retail pharmacy channels. The "enterprise app" for test management also suggests solutions designed for organizational deployment.
- Biopharmaceutical and Biotechnology Companies: Ainos' focus on developing a Synthetic RNA technology platform indicates potential partnerships, licensing agreements, or collaborative development initiatives with other companies within the biopharmaceutical and biotechnology sectors.
AI Analysis | Feedback
Chun-Hsien Tsai, Chairman of the Board of Directors, President & Chief Executive Officer
Mr. Tsai has served as Ainos' Chairman, President, and Chief Executive Officer since April 2021. He also held the role of Chief Financial Officer from April 2021 to August 2021. Prior to his current roles at Ainos, he served as the chairman and CEO of Taiwan Carbon Nano Technology Corporation (TCNT) since July 2018, a director of Ainos Inc. (Cayman Islands) since October 2017, and a director and CEO of AI Nose Corporation since 2016. Mr. Tsai has also been a director of TCNT since 2012. He holds an EMBA degree from National Yang Ming Chiao Tung University.
Christopher Lee, Chief Financial Officer
Mr. Lee has served as the Chief Financial Officer of Ainos since March 2024. He brings over 25 years of extensive experience in accounting and finance, with expertise in US GAAP, PCAOB standards, and SEC rules and regulations. Before joining Ainos, Mr. Lee spent 10 years as the CFO of another Nasdaq-listed company. His past experience also includes serving as a partner at KEDP CPA Group from August 2009 to June 2011 and operating as a self-employed accountant from July 2011 to August 2014. He has been a member of the Board of Directors of Aixin Life International Inc. since February 2021. Mr. Lee holds a BS degree in accounting from Ohio State University and an MS degree in business taxation from Golden Gate University, and he is a licensed Certified Public Accountant (CPA) in the United States.
Chun-Jung Tsai, Director
Mr. Tsai has served as a Director of Ainos since April 2021 and also works as a manager within the Company's sales team. His prior directorships include Ainos Inc. (Cayman Islands) since 2019, AI Nose Corporation since March 2016, and Taiwan Carbon Nano Technology Corporation (TCNT) since July 2012.
Ting-Chuan Lee, Director
Ms. Lee has been a Director of Ainos since April 2021 and serves as a manager at the CEO office. She has held the position of chairperson of AI Nose Corporation since March 2016 and has been a member of the board of directors of Taiwan Carbon Nano Technology Corporation (TCNT) since July 2012. Ms. Lee holds a master's degree of science from National Taiwan University.
Chung-Yi Tsai, Director
Mr. Tsai joined Ainos' Board of Directors in April 2021 and has been a director of TCNT since July 2012. He is an experienced executive in product and business development within the technology hardware sector, having served as a senior product marketing director at Alpha & Omega Semiconductor since May 2023. His previous roles include senior product marketing manager at Renesas Electronics (June 2020 - May 2023), executive business manager at Maxim Integrated (November 2019 - June 2022), and senior product marketing manager at Intersil Corporation (October 2013 - November 2019). Mr. Tsai earned a master's degree in business administration from Golden Gate University.
AI Analysis | Feedback
The key risks to Ainos, Inc.'s business (AIMD) primarily revolve around its precarious financial health and the significant challenges associated with the successful commercialization of its developing technologies.
- Poor Financial Health and Going Concern Risk: Ainos faces severe financial challenges, including consistently negative revenue growth, with a three-year decline of 82.3%. The company exhibits deeply concerning profitability metrics, with an operating margin of -12,678.76% and a net margin of -13,236.28%. Its Altman Z-Score, a measure of bankruptcy probability, is in the distress zone (e.g., -5.36 and -5.45), indicating a potential risk of bankruptcy within two years. The company is also "quickly burning through cash" and has not been profitable over the last twelve months. Additionally, Ainos carries significant liabilities that exceed its cash and near-term receivables, alongside a high debt-to-equity ratio of 1.1, suggesting considerable leverage. These factors raise substantial concerns about its ability to achieve profitability and secure additional capital in the future.
- Execution Risks in Product Development and Commercialization: Ainos's future depends heavily on the successful development and market adoption of its AI Nose platform and VELDONA therapeutics. While the company is transitioning its AI Nose platform to industrial implementation with initial orders, the progression into subsequent deployment phases is contingent upon successful technical validations, meeting specific milestones, and finalizing contractual agreements. The validation testing in advanced semiconductor facilities is critical for technical qualification and requires customer evaluations and formal approval before leading to commercial integration. Beyond technical hurdles, factors such as production costs, intense market competition, rapid technological advancements by rivals, and obtaining necessary regulatory approvals are significant challenges that could profoundly impact Ainos's future results and business prospects.
- High Stock Volatility and Negative Market Sentiment: Ainos's stock exhibits high volatility, with an 81.73% volatility rate and a beta of 1.12, suggesting significant price fluctuations. Technical indicators suggest a neutral to bearish market sentiment. The company has experienced a substantial decline in its stock price, with a one-year total return of -85.05%. This market perception is further evidenced by low institutional ownership and high insider ownership, potentially reflecting external investor confidence concerns. Ainos has also reported unusual trading patterns to regulators, suggesting potential market manipulation, which can further erode investor trust and contribute to price instability.
AI Analysis | Feedback
The significant and ongoing decline in global demand for COVID-19 diagnostic products, including rapid antigen test kits and nucleic acid tests, as the pandemic wanes and public health responses shift away from mass testing.
AI Analysis | Feedback
The addressable markets for Ainos' main products and services are as follows:
- COVID-19 Antigen Rapid Test Kit: The global COVID-19 rapid antigen test market was valued at USD 6.03 billion in 2024 and is projected to reach approximately USD 10.13 billion by 2032. Another estimate placed the global market size at USD 11.01 billion in 2023. The U.S. market for rapid COVID-19 antigen test kits is estimated at USD 3.5 billion in 2024. In 2022, Asia Pacific held the largest share of the global market, accounting for 37.0% of total revenue.
- COVID-19 Nucleic Acid Test: This falls under the broader COVID-19 diagnostics market, which includes molecular (PCR) tests. The global COVID-19 diagnostics market size was valued at USD 30.02 billion in 2024. Another source estimated the global COVID-19 detection kits market at USD 6.01 billion in 2023. The overall global COVID Testing Kit Market, which includes RT-PCR assay kits and rapid antigen testing, is expected to grow from USD 80.70 billion in 2024 to USD 173.40 billion by 2035.
- Volatile Organic Compounds (VOC) Point-of-Care Testing: The global Volatile Organic Compounds Testing Service Market was estimated at USD 2.87 billion in 2025 and is expected to reach USD 4.46 billion by 2032. A broader market, the global Volatile Organic Compound Market, was valued at USD 208.87 million in 2024 and is projected to grow to USD 400.46 million by 2033. The global point of care testing market, a broader category that includes VOC PoC testing, was estimated at USD 42 billion in 2024 and is projected to reach USD 82 billion by 2034.
- Very Low-Dose Oral Interferon Alpha: The global α-Interferon market size was valued at USD 10.11 billion in 2024 and is projected to reach USD 12.71 billion by 2030. More broadly, the global Interferons (IFNs) market, which encompasses alpha, beta, and gamma types, was valued at USD 9,736.63 million in 2024 and is projected to reach USD 13,843.44 million by 2032. North America is expected to dominate the overall interferon market.
- Synthetic RNA Technology Platform: Ainos' SRNA technology platform falls under the RNA therapeutics market. The global RNA therapeutics market was valued at USD 8.55 billion in 2025 and is projected to reach approximately USD 28.94 billion by 2035. The global RNA based therapeutic market was evaluated at US$ 6.83 billion in 2023 and is expected to attain around US$ 40.81 billion by 2034. North America dominated the RNA therapeutics market in 2024.
AI Analysis | Feedback
```htmlAinos (AIMD) is poised for future revenue growth over the next 2-3 years, driven by the expansion and commercialization of its AI Nose platform across various sectors, the ongoing development of its VELDONA therapeutic, and the adoption of its subscription-based business model for its technology offerings.
Drivers of Future Revenue Growth:
- Expansion of AI Nose Platform into Industrial Markets, particularly Semiconductor Manufacturing: Ainos is actively transitioning its AI Nose platform from pilot projects to industrial implementation, with a significant focus on the semiconductor industry. The company has secured an initial order for 1,400 AI Nose systems for semiconductor manufacturing, which is expected to generate approximately $2.1 million under a three-year subscription revenue model. A broader roadmap envisions the deployment of up to 20,000 AI Nose systems across customer facilities, potentially yielding annual orders nearing $10 million upon full execution and successful technical validation. This expansion is further supported by a distribution partnership with Trusval Technology aimed at penetrating the semiconductor sector and a collaboration with ASE Technology for integrating AI Nose into smart factory operations.
- Expansion of AI Nose into New Healthcare Applications and Markets: Beyond industrial uses, Ainos is targeting new applications for its AI Nose technology within the healthcare sector. This includes exploring opportunities in hospital operations for monitoring airborne viruses, assessing air quality in various hospital areas, and detecting leaks. Pilot programs for these applications are being considered in Taiwan. Additionally, AI Nose modules have been deployed in Japan to support hygiene monitoring in long-term care facilities. The company also continues to develop Ainos Flora, a point-of-care diagnostic for female vaginal health and STIs, with a second generation optimized for at-home testing undergoing clinical studies.
- Growth of the Subscription Revenue Model for AI Nose: Ainos is emphasizing and enhancing a subscription-based revenue model for its AI Nose deployments, particularly evident in the semiconductor manufacturing contracts. This model is expected to provide predictable, recurring revenue streams, which are crucial for the company's long-term financial stability and growth prospects. The company aims to further advance this model and its underlying infrastructure.
- Advancement and Commercialization of VELDONA Therapeutics: Ainos is progressing with its VELDONA platform, a low-dose oral interferon therapeutic. The clinical-stage pipeline includes VELDONA for human and animal oral therapeutics, as well as human orphan drugs. Notably, VELDONA has received clearance in Taiwan to commence clinical trials for HIV-related oral warts and primary Sjögren's syndrome. Continued veterinary trials and exploration of new indications for VELDONA also represent potential avenues for future revenue growth.
AI Analysis | Feedback
Share Issuance
- Ainos reported Net Common Stock Issued of approximately $1.85 million for the trailing twelve months ended September 2025.
- In fiscal year 2024, Ainos reported no issuance of common stock.
- In fiscal year 2022, the company issued common stock valued at approximately $1.78 million.
Inbound Investments
- Ainos secured a significant $2.1 million three-year subscription order from ASE Technology for semiconductor manufacturing applications, with deployments commencing in January 2026.
- The company's Cash from Financing Activities, which can include proceeds from equity or debt, was $8.0 million in fiscal year 2024, $4.92 million in fiscal year 2023, and $3.85 million in fiscal year 2022.
- Ainos issued long-term debt of $9.88 million in fiscal year 2024, $6 million in fiscal year 2023, and $2.2 million in fiscal year 2022.
Capital Expenditures
- Ainos's capital expenditures for the trailing twelve months ended September 2025 were approximately -$0.04 million.
- In the most recent quarter (Q3 2025), capital expenditures totaled approximately $10,000, representing a 231.9% increase from the prior quarter.
- Capital expenditures for fiscal year 2024 were approximately -$0.02 million, and for fiscal year 2023, they were approximately -$0.09 million.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Ainos Earnings Notes | 12/16/2025 | |
| Ainos Stock Drop Looks Sharp, But How Deep Can It Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to AIMD.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 153.14 |
| Mkt Cap | 79.1 |
| Rev LTM | 23,364 |
| Op Inc LTM | 7,070 |
| FCF LTM | 5,417 |
| FCF 3Y Avg | 5,463 |
| CFO LTM | 6,773 |
| CFO 3Y Avg | 6,518 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.3% |
| Rev Chg 3Y Avg | 5.0% |
| Rev Chg Q | 4.3% |
| QoQ Delta Rev Chg LTM | 1.0% |
| Op Inc Chg LTM | 21.7% |
| Op Inc Chg 3Y Avg | 8.2% |
| Op Mgn LTM | 28.2% |
| Op Mgn 3Y Avg | 25.1% |
| QoQ Delta Op Mgn LTM | -0.3% |
| CFO/Rev LTM | 27.3% |
| CFO/Rev 3Y Avg | 27.7% |
| FCF/Rev LTM | 23.3% |
| FCF/Rev 3Y Avg | 22.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 79.1 |
| P/S | 5.3 |
| P/Op Inc | 13.0 |
| P/EBIT | 12.7 |
| P/E | 19.5 |
| P/CFO | 14.1 |
| Total Yield | 6.6% |
| Dividend Yield | 2.5% |
| FCF Yield 3Y Avg | 3.7% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -4.4% |
| 3M Rtn | -6.7% |
| 6M Rtn | -11.7% |
| 12M Rtn | 17.9% |
| 3Y Rtn | 2.2% |
| 1M Excs Rtn | -10.5% |
| 3M Excs Rtn | -16.5% |
| 6M Excs Rtn | -22.2% |
| 12M Excs Rtn | -11.5% |
| 3Y Excs Rtn | -78.6% |
Price Behavior
| Market Price | $1.72 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -59.5% | |
| 50 Days | 200 Days | |
| DMA Price | $1.61 | $2.43 |
| DMA Trend | down | indeterminate |
| Distance from DMA | 7.1% | -29.1% |
| 3M | 1YR | |
| Volatility | 79.3% | 101.1% |
| Downside Capture | 302.59 | 403.50 |
| Upside Capture | 228.51 | 234.85 |
| Correlation (SPY) | 45.3% | 32.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.13 | 2.57 | 2.63 | 2.65 | 2.58 | 0.82 |
| Up Beta | 2.39 | 2.93 | 2.86 | 2.84 | 2.58 | 0.87 |
| Down Beta | -18.74 | -0.57 | -0.13 | 1.24 | 1.51 | 0.59 |
| Up Capture | 374% | 373% | 339% | 255% | 417% | 10% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 12 | 19 | 27 | 51 | 108 | 322 |
| Down Capture | 919% | 278% | 291% | 251% | 199% | 109% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 9 | 21 | 34 | 69 | 135 | 401 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AIMD | |
|---|---|---|---|---|
| AIMD | -38.5% | 101.0% | -0.05 | - |
| Sector ETF (XLV) | 13.2% | 15.0% | 0.62 | 6.6% |
| Equity (SPY) | 29.1% | 12.0% | 1.83 | 33.2% |
| Gold (GLD) | 42.9% | 26.8% | 1.30 | 10.9% |
| Commodities (DBC) | 44.5% | 18.5% | 1.84 | -7.0% |
| Real Estate (VNQ) | 12.1% | 13.4% | 0.60 | 5.6% |
| Bitcoin (BTCUSD) | -23.7% | 41.7% | -0.54 | 9.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AIMD | |
|---|---|---|---|---|
| AIMD | -55.2% | 130.1% | -0.29 | - |
| Sector ETF (XLV) | 5.1% | 14.6% | 0.17 | 0.3% |
| Equity (SPY) | 13.7% | 17.1% | 0.63 | 9.5% |
| Gold (GLD) | 20.0% | 17.9% | 0.91 | 5.7% |
| Commodities (DBC) | 10.7% | 19.4% | 0.44 | -3.3% |
| Real Estate (VNQ) | 3.2% | 18.8% | 0.07 | 3.3% |
| Bitcoin (BTCUSD) | 6.8% | 55.9% | 0.33 | 8.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AIMD | |
|---|---|---|---|---|
| AIMD | -23.3% | 140.8% | 0.14 | - |
| Sector ETF (XLV) | 9.6% | 16.5% | 0.47 | 5.7% |
| Equity (SPY) | 15.7% | 17.9% | 0.75 | 11.3% |
| Gold (GLD) | 13.4% | 15.9% | 0.69 | 4.8% |
| Commodities (DBC) | 8.3% | 17.9% | 0.38 | -1.5% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.22 | 5.7% |
| Bitcoin (BTCUSD) | 67.9% | 66.9% | 1.07 | 8.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/30/2026 | 3.0% | 9.6% | 27.4% |
| 11/13/2025 | -14.3% | -26.0% | -16.7% |
| 8/13/2025 | 13.7% | 3.0% | 6.0% |
| 3/7/2025 | -5.9% | 6.6% | 1.7% |
| 8/5/2024 | -6.5% | 6.3% | 15.1% |
| 3/8/2024 | -20.0% | -41.0% | -49.3% |
| 11/13/2023 | -3.2% | -0.8% | -14.4% |
| 8/11/2023 | 5.1% | -2.9% | -4.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 4 | 4 | 4 |
| # Negative | 5 | 5 | 5 |
| Median Positive | 4.1% | 6.4% | 10.5% |
| Median Negative | -6.5% | -3.7% | -16.7% |
| Max Positive | 13.7% | 9.6% | 27.4% |
| Max Negative | -20.0% | -41.0% | -49.3% |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chiang, Yao-Chung | Spouse | Buy | 5072026 | 1.70 | 129 | 219 | 1,409 | Form | |
| 2 | Chiang, Yao-Chung | Spouse | Buy | 5012026 | 1.68 | 200 | 336 | 1,176 | Form | |
| 3 | Chiang, Yao-Chung | Spouse | Buy | 5012026 | 1.75 | 100 | 175 | 875 | Form | |
| 4 | Taiwan, Carbon Nano Technology Corp | Direct | Sell | 1292026 | 2.17 | 46,000 | 99,806 | 2,147,840 | Form | |
| 5 | Taiwan, Carbon Nano Technology Corp | Direct | Sell | 1122026 | 1.86 | 431 | 802 | 1,926,820 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.